Celltrion, Inc. (068270) reduced enrollment in several phase three cancer biosimilar trials, Dailian reported Tuesday. The changes followed regulatory adjustments in Korea and overseas markets.
The company reduced the planned size of a US phase three trial for CT-P51. That candidate is a biosimilar version of the cancer drug Keytruda. Celltrion also simplified other cancer biosimilar trial plans, according to the report.
The report described the changes as recent amendments to ongoing studies. It did not provide a commercial launch date for CT-P51. The company's market capitalisation was ₩42.6 trillion at Tuesday's close.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 068270Celltrion, Inc. | ₩183,100 -1.7% |